Date: 2014-03-11
Type of information: Licensing agreement
Compound: HEPtune™ drug delivery system
Company: Caisson Biotech (USA) Novo Nordisk (Sweden)
Therapeutic area: Metabolic diseases - Inflammatory diseases - Autoimmune diseases
Type agreement: licensing
Action mechanism: HEPtune™ is an heparosan-based bio-superior drug delivery system that is designed to offer improved half-life, pharmacokinetics, pharmacodynamics, bioavailability, solubility and overall enhanced patient compliance and safety. Heparosan is a natural polymer composed of repeating units of N-acetylglucosamine and glucuronic acid.The body produces no extracellular enzymes that degrade heparosan, and there are no known receptors or binding proteins for heparosan.
Disease:
Details: * On March 11, 2014, Caisson Biotech, a US biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune™, has announced that it has expanded the scope of its partnership with global healthcare leader Novo Nordisk. This latest license agreement gives Novo Nordisk:
1) exclusive rights to commercialize insulin conjugated to HEPtune and
2) non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn\'s, lupus, rheumatoid and psoriatic arthritis.
Financial terms: Under the terms of the agreement, Caisson will be eligible to receive up to $167M in milestone payments upon achievement of certain predefined clinical, regulatory and commercial objectives plus potential long-term residual royalties.
Latest news:
